Literature DB >> 18813929

Less disease severity and favorable prognosis are associated with postmenopausal systemic lupus erythematosus patients.

Xiao Li Deng1, Xiang Yuan Liu.   

Abstract

The aim of this study is to characterize the clinical manifestations of postmenopausal systemic lupus erythematosus (SLE) patients. Of the 699 SLE inpatients, 20 postmenopausal and 70 menstruous SLE patients were evaluated and compared for the clinical manifestations. The mean age of onset was 55.05 years (range from 42 to 66) with a peak of 50-60 in postmenopausal lupus patients. The average time from SLE onset to diagnosis was 2.18 years. Arthritis was the most frequent initial manifestation in the postmenopausal group. Other common clinical manifestations and laboratory abnormalities include lassitude, fever, alopecia, malar rash, cardiac impairment and weight loss, and elevated ESR, decreased C3, ANA >or= 1:80, hypergammaglobulinemia and anti-RNP antibody positive. Compared with menstruous lupus patients, postmenopausal patients were more likely to have weight loss (P < 0.01), myalgia and myasthenia (P < 0.01), and less likely to have malar rash (P < 0.05), renal involvement (P < 0.01), leukocytopenia (P < 0.05) and positive ANA (P < 0.01). Thus, less disease severity and favorable prognosis were associated with postmenopausal SLE patients. Misdiagnosis and missed diagnosis were easy to make with their non-specific symptoms with fewer features suggestive of diagnosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813929     DOI: 10.1007/s00296-008-0724-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

1.  HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome.

Authors:  P Langevitz; D Buskila; D D Gladman; G A Darlington; V T Farewell; P Lee
Journal:  Br J Rheumatol       Date:  1992-09

2.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

Review 3.  The pathogenesis of autoimmunity in New Zealand mice.

Authors:  S Yoshida; J J Castles; M E Gershwin
Journal:  Semin Arthritis Rheum       Date:  1990-02       Impact factor: 5.532

4.  Hidden anti-nuclear antibodies in sero-negative systemic lupus erythematosus patients and in NZB and (NZB x NZW) F 1 mice.

Authors:  F J Blomjous; T M Feltkamp-Vroom
Journal:  Eur J Immunol       Date:  1971-11       Impact factor: 5.532

Review 5.  Atypical lupus with special reference to ANA negative lupus and lupus subsets.

Authors:  G R Hughes; R A Asherson
Journal:  Adv Nephrol Necker Hosp       Date:  1985

Review 6.  Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature.

Authors:  Jacques Boddaert; Du Le Thi Huong; Zahir Amoura; Bertrand Wechsler; Pierre Godeau; Jean-Charles Piette
Journal:  Medicine (Baltimore)       Date:  2004-11       Impact factor: 1.889

7.  Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.

Authors:  N Kanda; T Tsuchida; K Tamaki
Journal:  Arthritis Rheum       Date:  1999-02

8.  Estrogen decreases in vitro apoptosis of peripheral blood mononuclear cells from women with normal menstrual cycles and decreases TNF-alpha production in SLE but not in normal cultures.

Authors:  M J Evans; S MacLaughlin; R D Marvin; N I Abdou
Journal:  Clin Immunol Immunopathol       Date:  1997-03

9.  Systemic lupus erythematosus in the elderly: clinical and immunological characteristics.

Authors:  J Font; L Pallarés; R Cervera; A López-Soto; M Navarro; X Bosch; M Ingelmo
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

10.  Estrogen enhances immunoglobulin production by human PBMCs.

Authors:  N Kanda; K Tamaki
Journal:  J Allergy Clin Immunol       Date:  1999-02       Impact factor: 10.793

  10 in total
  1 in total

Review 1.  Menopause and Rheumatic Disease.

Authors:  Mitali Talsania; Robert Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2017-05       Impact factor: 2.670

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.